FDA cites in­creased death risk in de­ci­sion to yank ap­proval for TG Ther­a­peu­tics can­cer drug

Fol­low­ing pre­vi­ous­ly re­vealed safe­ty con­cerns, the FDA on Wednes­day said it has with­drawn TG Ther­a­peu­tics’ can­cer drug Ukoniq to treat two spe­cif­ic types of lym­phoma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER